AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer

Gianni, L.; Romieu, G.; Lichinister, M.; Serrano, S.; Mansutti, M.; Pivot, X.; Mariani, P.; Andre, F.; Chan, Arlene; Lipatov, O.; Chan, S.; Wardley, A.; Greil, R.; Moore, N.; Prot, S.; Pallaud, C.; Semiglazov, V.

Access Status

Fulltext not available

Authors

Gianni, L.

Romieu, G.

Lichinister, M.

Serrano, S.

Mansutti, M.

Pivot, X.

Mariani, P.

Andre, F.

Chan, Arlene

Lipatov, O.

Chan, S.

Wardley, A.

Greil, R.

Moore, N.

Prot, S.

Pallaud, C.

Semiglazov, V.

Date

2013

Type

Journal Article

Metadata

Show full item record

Citation

Gianni, L. and Romieu, G. and Lichinister, M. and Serrano, S. and Mansutti, M. and Pivot, X. and Mariani, P. et al. 2013. AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer. Journal of Clinical Oncology. 31 (14): pp. 1719-1726.

Source Title

Journal of Clinical Oncology